Compare Enovix Corporation (ENVX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs GSK plc — how do they compare? Enovix Corporation trades at $2.47 (market cap $549.72M), while GSK plc trades at $46.63 (market cap $91.88B). The key difference: GSK plc is far larger — about 167.1× Enovix Corporation's market cap, and GSK plc pays a 3.9% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and GSK plc for 93 Days on average.
| ENVX | GSK | |
|---|---|---|
Market Cap | $549.72M | $91.88B |
Volume | 6,635,687 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $13.19 | $61.18 |
52-Week Low | $2.50 | $43.24 |
Typical Hold Time | 11 Days | 93 Days |
Enterprise Value | $611.42M | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.46, down 3.53% on the day, reflecting a bearish technical trend. The company is in a high-growth investment phase, with revenue growing to $36 million in 2026 but reporting significant losses. Recent news highlights a CEO transition and progress in battery manufacturing for defense and consumer electronics, while analyst consensus remains largely positive with a $10.75 price target.
The outlook is bifurcated: strong analyst buy ratings and institutional interest signal long-term potential, but high cash burn, persistent losses, and bearish technical indicators present substantial near-term risks. Investment hinges on successful commercialization and achieving profitability from current expansion efforts.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
